A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
NCT ID: NCT05646862
Last Updated: 2026-02-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
420 participants
INTERVENTIONAL
2023-06-07
2029-03-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
NCT04191499
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT05894239
A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer
NCT04060862
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer
NCT04305496
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sub-study: Inavolisib + Fulvestrant + CYP substrates
Participants will be administered the treatments as outlined in the interventions section.
Inavolisib
Participants will be administered a 9 milligram (mg) inavolisib tablet orally once a day (PO QD) on Days 1-28 of each 28-day cycle of main study and sub-study.
Fulvestrant
Participants will be administered 500 mg of fulvestrant on Days 1 and 15 of Cycle 1 and then on Day 1 of each subsequent 28-day cycle of main study and sub-study.
Bupropion
Participants will be administered bupropion PO on Day -3 and Day 12 of Cycle 1 of the sub-study.
Omeprazole
Participants will be administered omerprazole PO on Day -4 and Day 11 of Cycle 1 of sub-study.
Midazolam
Participants will be administered midazolam PO on Day -4 and Day 11 of Cycle 1 of sub-study.
Inavolisib + Fulvestrant
Participants will be administered the treatments as outlined in the interventions section.
Inavolisib
Participants will be administered a 9 milligram (mg) inavolisib tablet orally once a day (PO QD) on Days 1-28 of each 28-day cycle of main study and sub-study.
Fulvestrant
Participants will be administered 500 mg of fulvestrant on Days 1 and 15 of Cycle 1 and then on Day 1 of each subsequent 28-day cycle of main study and sub-study.
Alpelisib + Fulvestrant
Participants will be administered the treatments as outlined in the interventions section.
Fulvestrant
Participants will be administered 500 mg of fulvestrant on Days 1 and 15 of Cycle 1 and then on Day 1 of each subsequent 28-day cycle of main study and sub-study.
Alpelisib
Alpelisib will be administered to participants at the approved dose in combination with fulvestrant: 300 mg taken PO QD and on days 1-28 of each 28-day cycle.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Inavolisib
Participants will be administered a 9 milligram (mg) inavolisib tablet orally once a day (PO QD) on Days 1-28 of each 28-day cycle of main study and sub-study.
Fulvestrant
Participants will be administered 500 mg of fulvestrant on Days 1 and 15 of Cycle 1 and then on Day 1 of each subsequent 28-day cycle of main study and sub-study.
Alpelisib
Alpelisib will be administered to participants at the approved dose in combination with fulvestrant: 300 mg taken PO QD and on days 1-28 of each 28-day cycle.
Bupropion
Participants will be administered bupropion PO on Day -3 and Day 12 of Cycle 1 of the sub-study.
Omeprazole
Participants will be administered omerprazole PO on Day -4 and Day 11 of Cycle 1 of sub-study.
Midazolam
Participants will be administered midazolam PO on Day -4 and Day 11 of Cycle 1 of sub-study.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically or cytologically confirmed adenocarcinoma of the breast that is locally advanced or metastatic and is not amenable to surgical or radiation therapy with curative intent
* Documented HR +/ HER2- tumor according to American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines
* Confirmation of biomarker eligibility: detection of specified mutation(s) of PIK3CA via specified test
* Disease progression after or during treatment with a combination of CDK4/6i and endocrine therapy: \<= 2 prior lines of systemic therapy in mBC setting; CDK4/6i based therapy does not need to be the last one received prior study entry; one line of chemotherapy in mBC setting allowed
* Measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
* Participants for whom endocrine-based therapy is recommended and treatment with cytotoxic chemotherapy is not indicated at time of entry into the study, as per national or local treatment guidelines
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2
* Life expectancy of \> 6 months
* Adequate hematologic and organ function prior to initiation of study treatment
Exclusion Criteria
* Prior treatment in locally advanced or metastatic setting with any PI3K, AKT, or mTOR inhibitor or any agent whose mechanism of action is to inhibit the PI3K/-AKT/-mTOR pathway
* Participant who relapsed with documented evidence of progression \> 12 months from completion of adjuvant CDK4/6i based therapy with no treatment for metastatic disease
* Type 2 diabetes requiring ongoing systemic treatment at the time of study entry; or any history of Type 1 diabetes
* Inability or unwillingness to swallow pills
* Malabsorption syndrome or other condition that would interfere with enteral absorption
* Any history of leptomeningeal disease or carcinomatous meningitis
* Known and untreated, or active central nervous system (CNS) metastases. Participants with a history of treated CNS metastases are eligible if they meet specific certain criteria
* Any concurrent ocular or intraocular condition that, in the opinion of the investigator, would require medical or surgical intervention during the study period to prevent or treat vision loss that might result from that condition
* Active inflammatory or infectious conditions in either eye or history of idiopathic or autoimmune-associated uveitis in either eye
* Requirement for daily supplemental oxygen
* Symptomatic active lung disease, including pneumonitis
* History of or active inflammatory bowel disease
* Any active bowel inflammation
* Clinically significant and active liver disease, including severe liver impairment, viral or other hepatitis, current alcohol abuse, or cirrhosis
* Participants with known human immunodeficiency virus infection that meet specific criteria
* History of other malignancy within 5 years prior to screening, except for cancers with very low risk of recurrence
* Chronic therapy of \>= 10 mg of prednisone per day or an equivalent dose of other anti-inflammatory corticosteroids or immunosuppressants for a chronic disease
* Active ongoing osteonecrosis of the jaw
* Pregnant, lactating, or breastfeeding, or intending to become pregnant during the study or at least 60 days after the final dose of study treatment
* Known active, systemic infection at study enrollment, or any major episode of infection requiring treatment with intravenous antibiotics or hospitalization within 7 days prior to Day 1 of Cycle 1
* Investigational drug(s) within 4 weeks before randomization or within 5 half-lives of the investigational drug(s), whichever is longer
* Allergy or hypersensitivity to components or excipients of the inavolisib, fulvestrant, or alpelisib formulations
* History of severe cutaneous reactions like Stevens-Johnson Syndrome, Erythema Multiforme, Toxic Epidermal Necrolysis, or Drug Reaction with Eosinphilia and Systemic Symptoms
* Pregnant, lactating, or breastfeeding, or intending to become pregnant during the substudy or within 2 weeks after the final dose of inavolisib and within 2 years after the final dose of fulvestrant, whichever is longer
* Known active, systemic infection at study enrollment, or any major episode of infection requiring treatment with intravenous antibiotics or hospitalization within 7 days prior to Day -4 of Cycle 1
* Investigational drug(s) within 4 weeks prior to Day -4 or within 5 half-lives of the investigational drug(s), whichever is longer
* Allergy or hypersensitivity to components or excipients of the inavolisib, fulvestrant formulations
* Treatment with mild, moderate, or strong inducers of CYP2B6, CYP3A4, and/or CYP2C19 (including St. John's Wort) within 14 days or 5 drug-elimination half-lives, whichever is longer, prior to initiation of study treatment on Day -4 until after the final PK sample has been collected on Day 15 of Cycle 1
* Treatment with mild, moderate, or strong inhibitors of CYP2B6, CYP3A4, and/or CYP2C19 (including grapefruit juice or supplements) within 14 days or 5 drug-elimination half-lives, whichever is longer, prior to initiation of study treatment on Day -4 until after the final PK sample has been collected on Day 15 of Cycle 1
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cancer Blood and Specialty Clinic
Los Alamitos, California, United States
Los Angeles Cancer Network
Los Angeles, California, United States
UC Davis Comprehensive Cancer Center
Sacramento, California, United States
Rocky Mountain Cancer Centers
Denver, Colorado, United States
Cleveland Clinic Florida
Weston, Florida, United States
Grady Health System
Atlanta, Georgia, United States
Midtown West Medical
Atlanta, Georgia, United States
Emory University Hospital
Atlanta, Georgia, United States
Winship Cancer Institute at Emory Saint Joseph's Hospital
Atlanta, Georgia, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Cancer & Hematology Centers of Western Michigan
Grand Rapids, Michigan, United States
Minnesota Oncology Hematology
Saint Paul, Minnesota, United States
Asante Rogue Regional Medical Center
Medford, Oregon, United States
Texas Oncology - Dallas Presbyterian Hospital
Dallas, Texas, United States
Centro de Investigaciones Médicas y Desarrollo LC S.R.L
Buenos Aires, , Argentina
Centro Oncologico Korben
Ciudad Autonoma Buenos Aires, , Argentina
Fundacion CORI para la Investigacion y Prevencion del Cancer
La Rioja, , Argentina
Instituto de Oncología de Rosario
Rosario, , Argentina
Hosp Provincial D. Centenarios
Rosario, , Argentina
CER San Juan Centro Polivalente de Asistencia e Investigacion Clinica
San Juan, , Argentina
Clinica Viedma S.A.
Viedma, , Argentina
Coffs Harbour Health Campus
Coffs Harbour, New South Wales, Australia
Concord Repatriation General Hospital
Concord, New South Wales, Australia
Kinghorn Cancer Centre
Darlinghurst, New South Wales, Australia
Gosford Hospital
Gosford, New South Wales, Australia
Icon Cancer Care Wesley
Auchenflower, Queensland, Australia
Bendigo Cancer Centre
Bendigo, Victoria, Australia
Sir Charles Gairdner Hospital
Perth, Western Australia, Australia
Cliniques Universitaires St-Luc
Brussels, , Belgium
GHdC Site Les Viviers
Charleroi, , Belgium
UZ Antwerpen
Edegem, , Belgium
UZ Gent
Ghent, , Belgium
UZ Leuven Gasthuisberg
Leuven, , Belgium
Clinique Ste-Elisabeth
Namur, , Belgium
NUPEC
Belo Horizonte, Minas Gerais, Brazil
Hospital Santa Cruz / Centro de Oncologia D'Or
Curitiba, Paraná, Brazil
Hospital do Cancer de Pernambuco - HCP
Recife, Pernambuco, Brazil
Instituto D?Or de Pesquisa e Ensino ? Hospital Esperança Recife
Recife, Pernambuco, Brazil
Liga Norte Riograndense Contra O Câncer
Natal, Rio Grande do Norte, Brazil
Santa Casa de Misericordia de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Hospital de Base de Sao Jose do Rio Preto
São José do Rio Preto, São Paulo, Brazil
Hospital Sírio-Libanês
São Paulo, São Paulo, Brazil
Arthur J.E. Child Comprehensive Cancer Center-Calgary
Calgary, Alberta, Canada
Cross Cancer Institute
Edmonton, Alberta, Canada
BC Cancer ? Vancouver
Vancouver, British Columbia, Canada
The Moncton Hospital
Moncton, New Brunswick, Canada
Juravinski Hospital
Hamilton, Ontario, Canada
The Ottawa Hospital - General Campus
Ottawa, Ontario, Canada
CIUSSS de l Est de l Ile de Montreal - Hopital Maisonneuve Rosemont
Montreal, Quebec, Canada
Centre Hospitalier de l'Universite de Montreal (CHUM)
Montreal, Quebec, Canada
Jewish General Hospital
Montreal, Quebec, Canada
Hôpital du Sacré-Coeur de Montreal
Montreal, Quebec, Canada
The First Hospital of Jilin University
Changchun, , China
Sichuan Provincial Cancer Hospital
Chengdu, , China
Sun yat-sen University Cancer Center
Guangzhou, , China
Guangdong Provincial People's Hospital
Guangzhou, , China
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, , China
Sir Run Run Shaw Hospital Zhejiang University
Hangzhou, , China
Harbin Medical University Tumor Hospital
Harbin, , China
The Second Affiliated Hospital to Nanchang University
Nanchang, , China
Jiangsu Cancer Hospital
Nanjing, , China
Tianjin Cancer Hospital
Tianjin, , China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, , China
Hubei Cancer Hospital
Wuhan, , China
First Affiliated Hospital of Medical College of Xi'an Jiaotong University
Xi'an, , China
Zhejiang Cancer Hospital
Zhejiang, , China
Centre Hospitalier de La Cote Basque
Bayonne, , France
Centre Leon Berard
Lyon, , France
ICM
Montpellier, , France
Centre Eugene Marquis
Rennes, , France
IUCT Oncopole
Toulouse, , France
Uniklinik RWTH Aachen Klinik für Gynäkologie und Geburtsmedizin
Aachen, , Germany
Universitätsklinikum Essen
Essen, , Germany
Praxis für Interdisziplinäre Onkologie und Hämatologie GbR
Freiburg im Breisgau, , Germany
Universitätsmedizin Göttingen Georg-August-Universität
Göttingen, , Germany
Mammazentrum Hamburg am Krankenhaus Jerusalem
Hamburg, , Germany
Medizinische Hochschule Zentrum Frauenheilkunde Abt.Gynäkologische Onkologie
Hanover, , Germany
Nationales Centrum für Tumorerkrankungen (NCT)
Heidelberg, , Germany
Brustzentrum Rhein-Ruhr Servicegesellschaft mbH
Mönchengladbach, , Germany
St. Vincenz-Krankenhaus GmbH Paderborn Frauen- und Kinderklinik St. Louise
Paderborn, , Germany
A.O. S. Anna e San Sebastiano
Caserta, Campania, Italy
IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola
Meldola, Emilia-Romagna, Italy
Ospedale San Raffaele
Milan, Lombardy, Italy
Ospedale Santa Chiara
Trento, Trentino-Alto Adige, Italy
Panamerican Clinical Research S.A de C.V.
Guadalajara, Jalisco, Mexico
RENATI INNOVATION S.A.P.I. de C.V
Guadalajara, Jalisco, Mexico
COI Centro Oncologico Internacional Santa Fe
Mexico City, Mexico CITY (federal District), Mexico
Health Pharma Professional Research
Mexico City, Mexico CITY (federal District), Mexico
OncoMed
Mexico City, Mexico CITY (federal District), Mexico
ARKE Estudios Clínicos S.A. de C.V.
Mexico City, Mexico CITY (federal District), Mexico
Instituto Nacional de Cancerologia
Distrito Federal, , Mexico
CENEIT Oncologicos
Mexico City, , Mexico
Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde
Morelia, , Mexico
Centrum Onkologii im. Prof. Franciszka ?ukaszczyka
Bydgoszcz, , Poland
Narodowy Instytut Onkologii Odzia? w Gliwicach
Gliwice, , Poland
Przychodnia Lekarska KOMED, Roman Karaszewski
Konin, , Poland
Szpital Wojewódzki im. Miko?aja Kopernika
Koszalin, , Poland
Szpital Uniwersytecki w Krakowie
Krakow, , Poland
MRUKMED Lekarz Beata Madej-Mruk i Partner Spolka Partnerska Oddzial nr 1 w Rzeszowie
Rzeszów, , Poland
Narodowy Instytut Onkologii im. M.Sklodowskiej-Curie
Warsaw, , Poland
Medical Oncology Centre of Rosebank
Johannesburg, , South Africa
Richards Bay Oncology Centre
KwaZulu Natal, , South Africa
Kyungpook National University Chilgok Hospital
Daegu, , South Korea
National Cancer Center
Goyang-si, , South Korea
Inha University Hospital
Incheon, , South Korea
Korea University Anam Hospital
Seoul, , South Korea
Seoul National University Hospital
Seoul, , South Korea
Severance Hospital, Yonsei University Health System
Seoul, , South Korea
Asan Medical Center
Seoul, , South Korea
Gangnam Severance Hospital
Seoul, , South Korea
Samsung Medical Center
Seoul, , South Korea
Seoul St Mary's Hospital
Seoul, , South Korea
ICO L'Hospitalet
L'Hospitalet de Llobregat, Barcelona, Spain
Hospital Universitario de Canarias
San Cristóbal de La Laguna, Tenerife, Spain
Hospital San Pedro De Alcantara
Cáceres, , Spain
Hospital General Universitario Gregorio Marañon
Madrid, , Spain
Hospital Ramon y Cajal
Madrid, , Spain
Hospital Universitario 12 de Octubre
Madrid, , Spain
Hospital Regional Universitario Carlos Haya
Málaga, , Spain
Hospital Universitario Virgen Macarena
Seville, , Spain
China Medical University Hospital
Taichung, , Taiwan
National Cheng Kung University Hospital
Tainan, , Taiwan
Taipei Veterans General Hospital
Taipei, , Taiwan
Chang Gung Memorial Hosipital at Linkou
Taoyuan, , Taiwan
Veterans General Hospital - Taichung
Xitun Dist., , Taiwan
National Taiwan University Hospital
Zhongzheng Dist., , Taiwan
Gulhane Training and Applicaton Hospital
Ankara, , Turkey (Türkiye)
Memorial Ankara Hastanesi
Ankara, , Turkey (Türkiye)
Dicle University Faculty of Medicine
Diyarbakır, , Turkey (Türkiye)
Trakya University Medical Faculty
Edirne, , Turkey (Türkiye)
Medipol Mega Üniversite Hastanesi Göztepe
Istanbul, , Turkey (Türkiye)
Marmara Uni Faculty of Medicine
Istanbul, , Turkey (Türkiye)
Ege Uni Medical Faculty Hospital
Izmir, , Turkey (Türkiye)
Katip Celebi University Ataturk Training and Research Hospital
Izmir, , Turkey (Türkiye)
Goztepe Prof.Dr. Suleyman Yalcin City Hospital
Kadiköy, , Turkey (Türkiye)
Hacettepe Uni Medical Faculty Hospital
Sihhiye/Ankara, , Turkey (Türkiye)
Basingstoke and North Hampshire Hospital
Basingstoke, , United Kingdom
Blackpool Victoria Hospital
Blackpool, , United Kingdom
Western General Hospital
Edinburgh, , United Kingdom
Princess Alexandra Hospital
Harlow, , United Kingdom
St Bartholomew's Hospital
London, , United Kingdom
Maidstone & Tonbridge Wells Hospital
Maidstone, , United Kingdom
Mount Vernon & Watford Hospital Trust
Northwood, , United Kingdom
Churchill Hospital
Oxford, , United Kingdom
Royal Hampshire County Hospital
Winchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
WO43919
Identifier Type: -
Identifier Source: org_study_id
2022-502322-41-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.